Alcohol and GLP-1 Medications: What the Evidence Shows

Alcohol y los medicamentos GLP-1: lo que dice la evidencia

It's Friday night, a glass is poured in front of you, and for the first time in years you don't feel the usual pull. It isn't a decision you made. The urge simply didn't arrive with its old force.

That scene is showing up more and more in patient forums, support groups, and follow-up visits for people on treatment with semaglutide or tirzepatide for weight or blood sugar. The question they almost always ask is the same: is this real, or am I just eating less overall and drinking less as a side effect of that?

There is a serious clinical trial behind that question. There is also a recent meta-analysis that tempers the enthusiasm. And there is a line SCTS1 will not cross: these medications are not approved to treat alcohol use disorder, and this is not a promise that you will stop drinking. This is an honest summary of what the science knows today — what it knows, and what it doesn't.

What thousands of people in treatment are asking

Over the past couple of years, a comment keeps showing up with striking regularity in patient forums and social media posts about semaglutide and tirzepatide: "I stopped wanting to drink," or "a drink tastes different now, I don't want the second one." It isn't why most people started treatment — they started for weight or blood sugar — but it's a side effect many report without having looked for it.

For a long time this stayed anecdotal. It no longer entirely is. There's a growing body of research — clinical trials, systematic reviews, and observational studies — trying to answer whether the effect is real, how large it is, and for whom.

The short answer, before the detail: the evidence is mixed, it's early, and it deserves to be told from both sides. That's exactly what we're going to do.

The trial that surprised researchers

The most-cited study on this topic was published in JAMA Psychiatry in 2025, led by a team from the University of North Carolina and the University of Southern California. It was a phase 2, randomized, double-blind clinical trial with 48 adults who met criteria for alcohol use disorder — not people seeking alcohol treatment, but participants recruited specifically for the study.

Over 9 weeks, one group received once-weekly injectable semaglutide at an ascending dose (0.25 mg, then 0.5 mg, then 1.0 mg) and the other received placebo. The primary outcome was measured with a laboratory alcohol self-administration task, before and after treatment.

An additional finding, in the subgroup who smoked cigarettes at baseline: semaglutide was also associated with a greater relative reduction in cigarettes per day. In other words, the effect didn't appear limited to alcohol.

The authors themselves were careful about the scope of their finding. They wrote that these results are initial prospective evidence that low-dose semaglutide can reduce craving and some drinking outcomes, and that they justify larger clinical trials — not that this is already proven.

It's a small study — 48 people — and phase 2, designed to detect a signal, not to confirm it with the strength of a phase 3 trial. That distinction matters a great deal for what comes next.

The brake: what the most recent meta-analysis says

In 2026, a team published in the journal Cureus a systematic review and meta-analysis that pooled the available randomized clinical trial evidence on GLP-1s and substance use disorders, including alcohol and tobacco. They combined 5 clinical trials with 764 participants, with follow-up ranging from 6 to 52 weeks.

This doesn't contradict the earlier trial as much as it puts it in context. The meta-analysis pools different studies, with different doses, different populations, and different ways of measuring "alcohol consumption." When all of that is combined, the signal that showed clearly in the low-dose trial gets diluted.

The meta-analysis authors are precise about it: current pooled evidence does not demonstrate a statistically significant benefit of GLP-1s for alcohol or tobacco outcomes. They note that a possible signal of benefit in people with comorbid alcohol use disorder and obesity should be interpreted as hypothesis-generating — a lead to investigate, not a conclusion — given the small number of trials, clinical heterogeneity, and imprecision of the estimates.

And they're equally clear about what's needed: adequately powered, longer-duration, agent-specific randomized trials with standardized substance-use outcomes, before this can be recommended in clinical practice.

This is exactly the kind of honesty an article on this topic needs. It would not be right to keep only the promising 2025 trial and leave out that the most recent, largest review didn't confirm the effect at that scale.

The other side: Reddit, 153 people, and real-world data

Between those two extremes sits a third type of evidence, different from a clinical trial: real-world, self-reported data that doesn't prove causation but shows what people are experiencing outside a laboratory.

A study published in Scientific Reports in 2023 by a team at the Fralin Biomedical Research Institute at Virginia Tech did two things. First, a machine-learning analysis of ~68,250 Reddit posts related to semaglutide or the GLP-1/GIP combination. They found eight major themes, and among comments specifically related to alcohol — 1,580 posts — 71% described reduced craving, decreased desire to drink, or other negative effects toward alcohol.

Second, a remote study with 153 people with obesity who drank alcohol: some had been taking semaglutide or tirzepatide for 30 days or more, and others took no medication (control group). Participants on medication reported significantly less alcohol intake, fewer drinks per occasion, lower odds of binge drinking, and lower AUDIT scores, compared both with their own baseline and with the control group.

This finding is consistent with the JAMA Psychiatry trial. But it needs to be read with the limitations it deserves: this is self-reported data, without the randomization or control of a clinical trial, and people who comment on social media or enroll in a remote study aren't necessarily representative of everyone taking these medications. It's another signal, not additional proof carrying the same weight as a controlled trial.

Why might this happen? The brain mechanism

The most-cited explanation has to do with where these medications act, not just how well they work.

GLP-1 receptors aren't only in the gut and pancreas, where they regulate digestion and insulin. They're also found in brain regions tied to reward and motivation — the same pathways activated by palatable food, and which in the addiction literature are also linked to alcohol and other substances.

The hypothesis, summarized in a perspective published in the Journal of General Internal Medicine in 2025, is that these medications may dampen the response of those shared reward circuits. That same perspective reviewed, alongside the clinical trial, three retrospective studies that found associations between GLP-1 use and lower incident and recurrent alcohol use disorder, lower alcohol intoxication among people with the disorder, and fewer hospitalizations related to alcohol and other substance use.

There's ongoing research that goes beyond alcohol: a clinical trial protocol is underway evaluating semaglutide as an adjunctive treatment for cocaine use disorder, and another evaluated liraglutide in opioid use disorder. This suggests that, if the mechanism is real, it may not be alcohol-specific but tied to reward circuits more broadly.

All of this remains, in the researchers' own words, a developing area of hypothesis. The mechanism is plausible and has support in animal models, but the evidence in humans — as we saw in the previous section — is not yet conclusive.

What changes if you're already on a GLP-1 program

If you're already in treatment and notice that alcohol calls to you less, you're not imagining something with no scientific basis — there are studies documenting exactly that experience. But it's important to be precise about what that change means and doesn't mean.

It doesn't mean your medication was prescribed for that purpose, and it doesn't replace an evaluation for alcohol use disorder if that's your situation. Once you start your program, a licensed physician reviews your case — habits, stress, sleep and medical history — and orders labs only if they consider it necessary. That process is designed around your treatment goal — weight, metabolic health, hormonal health — not around treating alcohol consumption as a diagnosis.

If the effect shows up, it's reasonable to mention it at your next follow-up visit: it helps your provider understand how you're responding to treatment overall. If it doesn't show up, that doesn't mean treatment isn't working for what it was actually prescribed for — the effects on weight and metabolism don't depend on this mechanism.

Eligibility for any program is determined by medical evaluation, and no article can replace that conversation.

Safety: what to know if you drink while on treatment

Beyond craving, there's a practical question almost nobody asks before starting: does alcohol feel different in the body while you're on GLP-1 treatment?

GLP-1 medications slow gastric emptying — that's part of how they create fullness — and nausea is one of the most common side effects, especially early on or when increasing dose. Combining that with alcohol, which also irritates the stomach and affects judgment, can intensify nausea or digestive discomfort in some people, though there's no universal "how much is safe" table because it depends on dose, individual tolerance, and other medications.

This isn't meant to alarm anyone or serve as a blanket prohibition. It's information to bring to your visit. If you drink regularly, mention it to your provider when you start treatment, and again if you notice changes — in either direction — in how it affects you.

What this evidence does NOT say

Let's be explicit, because enthusiasm on social media tends to outrun the science on this topic.

It does not say GLP-1s are a treatment for alcohol use disorder. They are not FDA-approved for that use, and the most recent pooled evidence doesn't even confirm the effect with statistical significance.

It does not say you will stop drinking. The most favorable trial measured reductions in grams of alcohol and craving, in a specific group of 48 people — not guaranteed abstinence.

It does not say it's safe to combine alcohol and GLP-1s without limit. None of the studies cited here evaluated that as a primary question.

It does not say treatment is failing if you don't feel the effect. The mechanism, if it exists, is independent of the metabolic effects most people start treatment for.

And it does not say how much will change for you. Individual results vary and are not guaranteed.

Who is this NOT for?

This article is not for you if you have a diagnosed alcohol use disorder, or suspect you do, and you're looking here for treatment. That deserves an evaluation with an addiction specialist or a dedicated treatment program — not a medication prescribed for a different indication in the hope of a side effect. Asking for that help is not a failure; it's the right step, and specialized helplines exist for exactly this.

It's also not for you if you're considering stopping a prescribed alcohol-use medication and replacing it with a GLP-1 based on this article. That decision, if it ever makes sense, belongs to the professional managing your addiction treatment, not to an informational article.

It's not for you if you have a physical dependence on alcohol where stopping abruptly can be dangerous. That situation requires supervised medical management, regardless of any other treatment you're considering.

And it's not for you if you're looking for a reason to start a GLP-1 program based solely on this possible effect on alcohol. Eligibility for our programs is assessed based on your weight and metabolic health goals; the effect on alcohol craving, if it shows up, is a finding from ongoing research, not the reason these treatments are designed.

It is for you if you're already in treatment and wondered whether what you're noticing has scientific backing, or if you simply wanted to understand how solid — or not — this conversation that's become so common really is.

See the programs

GLP-1 programs from $88.99/month. Care in English and Spanish, 100% by telemedicine.

Frequently Asked Questions

Do GLP-1 medications reduce the urge to drink alcohol?

A randomized clinical trial published in JAMA Psychiatry in 2025 found that low-dose semaglutide reduced weekly alcohol craving and consumption in a laboratory self-administration task, compared with placebo, in 48 adults with alcohol use disorder. It's a real but preliminary finding — a small phase 2 study, not an approval or a clinical indication.

So is it proven to work?

No. A meta-analysis published in 2026 in Cureus, combining five randomized clinical trials with 764 participants, found no statistically significant effect of GLP-1s on days without alcohol consumption. The authors themselves describe the evidence as low to moderate certainty and call for larger trials before drawing conclusions.

Why is there so much social media discussion about this?

A study published in Scientific Reports in 2023 analyzed roughly 68,250 Reddit posts and found that, among alcohol-related comments, 71% described reduced craving or reduced desire to drink. The same team ran a remote study with 153 people and found lower self-reported alcohol consumption among those taking semaglutide or tirzepatide compared with a control group. This is self-reported data, not a controlled clinical trial with the same strength as the trial above.

Does SCTS1 prescribe GLP-1s to help people stop drinking?

No. GLP-1 medications are not FDA-approved for alcohol use disorder, and SCTS1 does not prescribe medication or promote it for that use. If you have a problem with alcohol, the right path is an evaluation with an addiction specialist.

Is it safe to drink alcohol while on a GLP-1 program?

That depends on your case and should be discussed with your provider. What the literature does document is that GLP-1s can delay gastric emptying and that nausea is a common side effect, which can change how alcohol feels in the body. This isn't meant to alarm anyone — it's information to bring to your visit.

Why would a diabetes or weight medication affect alcohol craving?

The best-supported hypothesis is that GLP-1 receptors aren't only in the gut and pancreas — they also appear in brain regions tied to reward and motivation. Preclinical research suggests these medications may dampen reward circuits shared by food, alcohol, and other substances. It's a proposed mechanism, not a fact demonstrated in humans with the same certainty as other effects of these drugs.

Do you offer care in Spanish?

Yes. All of our content and care are available in both English and Spanish.

Sources

• Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. — DOI · via PubMed
• Sarma I, et al. A Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders. Cureus. 2026;18(6):e111641. — DOI · via PubMed
• Lira MC, Barrett E, Coffey MJ. GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder. J Gen Intern Med. 2025;40(12):2997-2999. — DOI · via PubMed
• Quddos F, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023;13(1):20998. — DOI · via PubMed
• Yammine L, et al. Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial. BMJ Open. 2026;16(5):e115675. — DOI · via PubMed

Your trust is worth more than a sale.

Learn more →

This article is informational and is not medical advice. GLP-1 medications are not FDA-approved for alcohol use disorder; the alcohol-related information in this article describes ongoing research, not a treatment indication. SCTS1 does not prescribe medication. All medical care, prescriptions, and treatment plans are provided by licensed healthcare providers through our partner platform. Treatment eligibility is determined by a licensed provider. Compounded medications contain the same active ingredient class but are not FDA-approved finished pharmaceuticals. Individual results vary and are not guaranteed. If you have a problem with alcohol use, consult a health professional or an addiction specialist before making any change to your treatment.